News RFK Jr cancels $500m in funding for mRNA vaccines RFK Jr is cutting $500m in funding for mRNA vaccines for diseases like flu and COVID-19, but critics say his reasons for doing so are spurious.
News Vertex is smarting from a pain portfolio setback Shares in Vertex Pharma have come under pressure after one of its non-opioid pain candidates failed to move the needle in a mid-stage trial.
News Gates Foundation puts $2.5bn into 'ignored' women's health The Gates Foundation is ramping up support for women's health research, pumping $2.5bn into new projects in this 'ignored, underfunded' area of R&D.
News After phase 3 hit, Spine seeks path forward for pain drug The first phase 3 readout with Spine BioPharma's drug candidate for chronic low back pain has proved disappointing.
News ChatGPT can cut review times for clinical trial eligibility ChatGPT can't replace humans when it comes to checking patient eligibility to take part in clinical trials, but it can save time and money.
News Lilly trumpets heart health data with Mounjaro Eli Lilly has raised the stakes in its rivalry with Novo Nordisk on GLP-1 drugs for diabetes, with new data for Mounjaro on cardiovascular outcomes.
News Outlook blindsided as FDA blocks wet AMD drug once again Shares in Outlook Therapeutics lost more than half their value after the FDA turned down the company's marketing application for its wet AMD therapy.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face